Moolec Science Secures Regulatory Approval for Safflower GLASO Technology in Argentina, Expands U.S. Acreage, and Strengthens Leadership With CFO Appointment
Moolec Science (NASDAQ:MLEC), a biotechnology company focused on engineering plants and microbes for protein solutions, announced three significant developments. First, the company received regulatory approval from SENASA in Argentina for its safflower GLASO technology, enabling expansion of its GLA-enriched safflower crop production. Second, Moolec has doubled its U.S. safflower acreage compared to last year, strengthening its supply capabilities for the pet food and human nutrition markets.
Additionally, the company appointed Valeria Falottico as CFO, bringing over 20 years of financial expertise. Moolec also completed the integration of Mycofood™, its fungal-based protein platform, which is currently developing products for evaluation by food industry partners in North America and Europe.
Moolec Science (NASDAQ:MLEC), una società biotecnologica specializzata nell’ingegneria di piante e microrganismi per soluzioni proteiche, ha annunciato tre sviluppi rilevanti. Innanzitutto, ha ottenuto la approvazione regolatoria da SENASA in Argentina per la sua tecnologia GLASO sul cartamo, permettendo di ampliare la produzione di cartamo arricchito in GLA. In secondo luogo, Moolec ha raddoppiato gli ettari di cartamo coltivati negli USA rispetto all’anno scorso, potenziando la sua capacità di approvvigionamento per i mercati di alimenti per animali e nutrizione umana.
Inoltre, la società ha nominato Valeria Falottico come CFO, che porta oltre 20 anni di esperienza finanziaria. Moolec ha anche completato l’integrazione di Mycofood™, la sua piattaforma proteica a base fungina, ora in fase di sviluppo di prodotti che verranno valutati da partner dell’industria alimentare in Nord America e in Europa.
Moolec Science (NASDAQ:MLEC), una biotecnológica centrada en la ingeniería de plantas y microbios para soluciones proteicas, anunció tres avances importantes. Primero, la compañía recibió la aprobación regulatoria de SENASA en Argentina para su tecnología GLASO en cártamo, lo que permite ampliar la producción de cártamo enriquecido con GLA. Segundo, Moolec ha duplicado las hectáreas de cártamo en EE. UU. respecto al año pasado, reforzando su capacidad de suministro para los mercados de alimentos para mascotas y nutrición humana.
Además, la empresa nombró a Valeria Falottico como CFO, aportando más de 20 años de experiencia financiera. Moolec también completó la integración de Mycofood™, su plataforma de proteína basada en hongos, que actualmente desarrolla productos para evaluación por parte de socios de la industria alimentaria en Norteamérica y Europa.
Moolec Science (NASDAQ:MLEC)는 단백질 솔루션을 위해 식물과 미생물을 설계하는 데 주력하는 생명공학 회사로, 세 가지 주요 소식을 발표했습니다. 첫째, 아르헨티나의 SENASA로부터 GLASO 기술에 대한 규제 승인을 받았으며, 이를 통해 GLA가 강화된 홍화(사프플라워) 작물 생산을 확대할 수 있게 됐습니다. 둘째, Moolec은 작년보다 미국 내 홍화 재배 면적을 두 배로 늘렸어 반려동물 사료 및 인간 영양 시장에 대한 공급 역량을 강화했습니다.
또한 회사는 20년 이상의 재무 경험을 보유한 발레리아 팔로티코를 CFO로 임명했으며, Moolec은 곰팡이 기반 단백질 플랫폼인 Mycofood™의 통합을 완료해 현재 북미와 유럽의 식품업계 파트너들이 평가할 제품들을 개발 중입니다.
Moolec Science (NASDAQ:MLEC), une société de biotechnologie spécialisée dans l’ingénierie de plantes et de micro-organismes pour des solutions protéiques, a annoncé trois avancées importantes. Premièrement, la société a obtenu l’approbation réglementaire de SENASA en Argentine pour sa technologie GLASO sur le carthame, ce qui permet d’étendre la production de carthame enrichi en GLA. Deuxièmement, Moolec a doublé sa superficie de carthame aux États-Unis par rapport à l’an dernier, renforçant ainsi ses capacités d’approvisionnement pour les marchés de l’alimentation pour animaux de compagnie et de la nutrition humaine.
Par ailleurs, la société a nommé Valeria Falottico au poste de CFO, qui apporte plus de 20 ans d’expérience financière. Moolec a également finalisé l’intégration de Mycofood™, sa plateforme de protéines à base fongique, qui développe actuellement des produits destinés à être évalués par des partenaires de l’industrie agroalimentaire en Amérique du Nord et en Europe.
Moolec Science (NASDAQ:MLEC), ein Biotechnologieunternehmen, das Pflanzen und Mikroben für Proteinlösungen entwickelt, hat drei bedeutende Entwicklungen bekannt gegeben. Erstens erhielt das Unternehmen die regulatorische Zulassung von SENASA in Argentinien für seine GLASO-Technologie bei Saflor, was die Ausweitung der Produktion von GLA-angereichertem Saflor ermöglicht. Zweitens hat Moolec die Saflor-Anbaufläche in den USA im Vergleich zum Vorjahr verdoppelt und damit seine Versorgungskapazitäten für die Heimtierfutter- und Humanernährungs‑Märkte gestärkt.
Darüber hinaus ernannte das Unternehmen Valeria Falottico zur CFO, die über mehr als 20 Jahre finanzielle Erfahrung verfügt. Moolec hat außerdem die Integration von Mycofood™, seiner pilzbasierten Proteinplattform, abgeschlossen, die derzeit Produkte für die Prüfung durch Lebensmittelindustrie‑Partner in Nordamerika und Europa entwickelt.
- Regulatory approval in Argentina for safflower GLASO technology expands market access
- Doubled U.S. safflower acreage demonstrates scalability and growth
- Appointment of experienced CFO with 20+ years in financial markets strengthens leadership
- Successful integration of Mycofood™ platform diversifies protein technology portfolio
- Ongoing restructuring process indicates organizational challenges
- Multiple technology platforms may require significant capital investment
Insights
Moolec strengthens position in alternative proteins through regulatory approval, production expansion, and organizational development.
Moolec Science has achieved three significant milestones that collectively strengthen its molecular farming platform. First, the SENASA regulatory approval in Argentina for their safflower GLASO technology represents a critical validation of their molecular farming approach. This approval enables expansion of their GLA-enriched safflower crop and establishes a foundation for counter-seasonal production strategies between hemispheres, which could significantly enhance supply chain resilience.
The doubling of U.S. safflower acreage compared to the previous year demonstrates growing commercial traction and scalability of their technology. This expansion directly supports revenue-generating activities with partners in pet food and human nutrition, indicating market validation of their specialty oils.
Beyond their plant-based platform, Moolec has completed integration of Mycofood™, expanding their technology portfolio to include fungal precision fermentation. This diversification is strategically sound, as it positions Moolec to capture value across multiple protein production systems with different technological and commercial maturity timelines. The advancement of fungal protein ingredients with food industry partners in North America and Europe indicates commercial development progress beyond their plant molecular farming core.
These developments collectively demonstrate Moolec's execution capabilities in translating biotechnology innovations into commercially viable products with established regulatory pathways. The company is systematically building the foundation elements required for alternative protein technology commercialization: regulatory approvals, production scaling, and diversified technology platforms.
The appointment of Valeria Falottico as CFO brings valuable continuity and capital markets expertise at a critical juncture for Moolec. With over 20 years of experience across consulting, financial services, and capital markets, her background in capital raising, IPOs, and M&A provides Moolec with seasoned financial leadership as they transition from development to commercialization.
The company's doubling of safflower acreage in the U.S. represents a direct investment in commercial inventory buildup, indicating growing confidence in market demand for their GLASO technology outputs. This expanded production capability should positively impact revenue potential in the near term, particularly as they mention existing relationships with global players in pet food and human nutrition industries.
The regulatory approval in Argentina for Moolec's safflower technology establishes a valuable geographic diversification strategy. By enabling counter-seasonal production between Northern and Southern hemispheres, Moolec can potentially achieve more consistent year-round supply capabilities - addressing a common challenge for agricultural biotechnology companies dependent on growing seasons.
The integration of Mycofood™ represents strategic diversification of their technology portfolio beyond molecular farming into precision fermentation. This multi-platform approach reduces technology risk while creating multiple potential commercialization pathways. With commercial development already underway with food industry partners, this suggests potential revenue streams from different technological approaches on varying timelines.
These developments collectively demonstrate progress on three critical fronts for an early-stage biotechnology company: regulatory pathway advancement, production scaling, and organizational development - all essential elements for translating innovation into sustainable commercial operations.
WARWICK, GB / ACCESS Newswire / September 11, 2025 / Moolec Science Limited, a wholly-owned subsidiary of Moolec Science SA (NASDAQ:MLEC)("the Company"; "Moolec"), an innovation-driven company engineering plants and microbes to unlock scalable protein solutions for the global food industry, today announced regulatory approval in Argentina for its safflower GLASO[1] technology, the expansion of U.S. acreage to support revenue-generating activities, and the appointment of a new Chief Financial Officer to strengthen its leadership team.
Regulatory Milestone for GLASO[1] Technology in Argentina
In Argentina, the National Service for Agri-Food Health and Quality (SENASA) granted feed and food approval for Moolec's proprietary Safflower GLASO[1] technology. This milestone enables the Company to expand its unique safflower crop enriched in gamma-linolenic acid (GLA), a high-value specialty oil with nutritional and industrial applications. The approval not only validates Moolec's molecular farming approach in oilseeds, but also establishes the regulatory foundation to support future counter-season supply strategies in Argentina, enhancing supply chain flexibility and positioning the Company for future commercial expansion into new markets.
Expansion of U.S. Safflower Season
In the United States, Moolec is advancing its safflower production season with duplicated acreage compared to last year's crop. This expansion demonstrates the scalability and reliability of the Company's GLASO[1] technology and is expected to significantly increase commercial inventory. By strengthening its supply base, Moolec is reinforcing its ability to meet the growing demand from leading global players in the pet food and human nutrition industries, while supporting the long-term commercialization of specialty oils.
"The progress of our U.S. safflower season, coupled with the regulatory green light in Argentina, demonstrates Moolec's ability to execute its science and translate it into scalable, tangible outcomes. These steps directly reinforce our commitment to delivering reliable, high-quality supply to our partners. At the same time, the integration of Mycofood™ expands our technological base beyond molecular farming into fungal precision fermentation, adding a new layer of protein solutions under commercial development in North America and Europe," said Alejandro Antalich, Chief Executive Officer of Moolec Science.
Strengthening Leadership Team
Moolec has appointed Valeria Falottico as its new Chief Financial Officer, providing continuity after CEO Alejandro Antalich temporarily assumed the role on an interim basis during the Company's restructuring.
"We are thrilled to welcome Valeria as our new CFO. Her extensive capital markets expertise and proven leadership within Moolec make her the ideal financial steward as we enter our next phase of integration and expansion. Her appointment underscores our commitment to strengthening the trust of both current and new shareholders, while ensuring disciplined capital allocation aligned with our vision for growth," said Mr. Antalich.
Ms. Falottico brings more than 20 years of experience in consulting, financial services, and capital markets across the U.S., Asia and Latin America. She has held senior leadership roles in multinational organizations, driving capital raising, IPOs, M&A, and other strategic transactions.
She joined Moolec in 2023 and has since held several key leadership roles in financial and compliance reporting. Prior to Moolec, she served in senior positions at NASDAQ trading public company dLocal and PayClip, and earlier spent 17 years at PricewaterhouseCoopers in Argentina and Mexico, advising clients worldwide. She holds an Accounting degree and an MBA from IAE Business School.
"I am honored to assume the role of CFO at such a pivotal time for Moolec," said Ms. Falottico. "I look forward to contributing to the Company's growth, financial discipline, and long-term value creation for all stakeholders."
Expanding Protein Technology Portfolio
Moolec has completed the integration of Mycofood™, now structured as a dedicated platform for fungal-based alternative proteins via precision fermentation. The platform's lead fungal protein ingredient is advancing through commercial development with applications under evaluation by leading food industry partners in North America and Europe. This diversification complements Moolec's molecular farming programs, enhancing its ability to capture value across multiple next-generation protein production systems.
These milestones reinforce the Company's position as an emerging leader at the intersection of biotechnology and food production, supported by a differentiated portfolio designed to deliver sustainable growth and long-term shareholder value.
Forward Looking Statements
This press release contains "forward-looking statements." Forward-looking statements may be identified by the use of words such as "forecast," "intend," "seek," "target," "anticipate," "believe," "expect," "estimate," "plan," "outlook," and "project" and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Such forward-looking statements with respect to performance, prospects, revenues, and other aspects of the business of Moolec are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that these statements are based on a combination of facts and factors, about which we cannot be certain. We cannot assure you that the forward-looking statements in this press release will prove accurate. These forward-looking statements are subject to a number of significant risks and uncertainties that could cause actual results to differ materially from expected results, including, among others, changes in applicable laws or regulations, the possibility that Moolec may be adversely affected by economic, business and/or other competitive factors, costs related to the scaling up of Moolec's business and other risks and uncertainties, including those included under the header "Risk Factors" in Moolec's Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission ("SEC"), as well as Moolec's other filings with the SEC. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Accordingly, you should not put undue reliance on these statements.
[1] Pat. US11/438,951 and US13/025,345
Contact Information
Press & Media
comms@moolecscience.com
Investor Relations
ir@moolecscience.com
SOURCE: Moolec Science
View the original press release on ACCESS Newswire
FAQ
What regulatory approval did Moolec Science (MLEC) receive in Argentina?
How much has Moolec Science expanded its U.S. safflower production in 2025?
Who is the new CFO of Moolec Science (MLEC)?
What is Mycofood™ and how does it fit into Moolec's business?
What markets is Moolec Science targeting with its GLASO technology?
